ClinicalTrials.gg
Active, not recruitingNCT06265428Updated Oct 30, 2026

A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

A Phase 3 interventional study of DB-1303/BNT323 and T-DM1 in HER2-positive Breast Cancer, sponsored by DualityBio Inc.. Active, not recruiting at 48 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by DualityBio Inc. · Phase 3, Interventional, and Treatment

Updated Oct 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,930 studies in Breast Neoplasms with a site in China — 868 open to participants now, 1,065 under way, 210 of them phase 3. Breast Neoplasms · China.

Enrollment
506th of 1,520
228 · median 120
Started
2024
with 221 others
Phase 3
331 of 1,930
120 open now
Primary completion
2027-12
later than 753 of 1,064 live
Registered
1,242nd of 1,930
by date

Among the 1,930 studies in Breast Neoplasms with a site in China, this one is the 506th largest by enrollment of the 1,520 interventional ones that give a count, is one of 222 that started in 2024, is one of 331 in phase 3, reaches primary completion later than 753 of the 1,064 other live ones, and was the 1,242nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

868 of the 1,930 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

863 more — sign in →

All 868 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,930 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is designed to compare efficacy and safety of DB-1303/BNT323 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.

Read the detailed description

This is a randomized controlled, 2-arm, open-label, multicenter phase III study to assess the efficacy and safety of DB-1303/BNT323 versus Trastuzumab Emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2) -positive unresectable/metastatic breast cancer who have been treated with trastuzumab and taxanes. Approximately 224 patients with unresectable or metastatic HER2-positive breast cancer will be randomized 1:1 to receive DB-1303/BNT323 or T-DM1, respectively.

03

Conditions studied

  • HER2-positive Breast Cancer

Browse trials for

Keywords

  • HER2-positive
  • Breast Cancer
  • BC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female adults ≥ 18 years at the time of voluntary signing of .
  • confirmed unresectable or positive breast cancer previously treated with trastuzumab and taxane
  • (ECOG) performance status score is 0 or 1.
  • Presence of at least one according to v1.1
  • Expected survival time ≥ 12 weeks.
  • Patients must give informed consent to this study and voluntarily sign written informed consent form prior to the study.

Exclusion criteria

Exclusion Criteria:

  • Prior anti- ADC therapy.
  • Previous history of interstitial lung disease/noninfectious pneumonitis/radiation pneumonitis requiring therapy.
  • Known serious to the active ingredients of the study drug, inactive ingredients in the formulation, or other antibody drugs.
  • Multiple primary within 3 years, except for adequately resected non-melanoma skin cancer, curatively treated in situ tumor, or contralateral breast cancer
  • Uncontrolled infection requiring intravenous antibiotics, antiviral or antifungal agents, disease requiring treatment, uncontrolled diabetes, hypertension, or other systemic disease that makes compliance with study procedures difficult
  • Unrecovered toxicity from prior anticancer therapy, defined as toxicity (except for alopecia) not recovered to ≤Grade 1 ( v5.0) or baseline.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
228 participants (actual)

Study arms

  • Experimental
    DB-1303/BNT323

    Enrolled patients will receive DB-1303/BNT323 by intravenous (I.V.) infusion

    Drug: DB-1303/BNT323

  • Experimental
    T-DM1

    Enrolled patients will receive T-DM1 by I.V. infusion

    Drug: T-DM1

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    Defined as the time from randomization to the first documented disease progression per RECIST 1.1 as assessed by BICR or death due to any cause, whichever occurs first

    Time frame: Up to approximately 24 months.

Secondary outcomes

  1. Overall Survival (OS)

    Defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 24 months.

  2. Progression Free Survival (PFS) by Investigator assessment per RECIST 1.1

    Defined as the time from randomization to the first documented disease progression per RECIST 1.1 as assessed by investigator or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 24 months.

  3. Objective response rate (ORR) by BICR and investigator assessment per RECIST 1.1

    Defined as the percentage of patients who have a complete response (CR) or partial response (PR) per RECIST 1.1 as assessed by BICR and investigator assessment.

    Time frame: Up to approximately 24 months.

  4. Duration of response (DoR) by BICR and investigator assessment per RECIST 1.1

    Defined as the time from first response (CR or PR) to subsequent disease progression per RECIST 1.1 as assessed by BICR and investigator assessment, or death from any cause, whichever occurs first.

    Time frame: Up to approximately 24 months.

  5. PK parameters: maximum observed concentration (Cmax)

    Maximum observed concentration (Cmax) of DB-1303/BNT323 Antibody-drug conjugate (ADC) and free toxin P1003, etc. after DB-1303/BNT323 administration

    Time frame: Up to approximately 24 months.

  6. PK parameters: time to maximum concentration (Tmax)

    Time to maximum concentration (Tmax) of DB-1303/BNT323 ADC and free toxin P1003, etc. after DB-1303/BNT323 administration

    Time frame: Up to approximately 24 months.

  7. Adverse events (AEs)

    Number and percentage of patients who report serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), TEAEs leading to study drug discontinuation, adverse events of special interest (AESIs) (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0\[NCI-CTCAE v5.0\])

    Time frame: Up to approximately 24 months.

  8. Patient reported outcomes (PROs): European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) - C30

    Change from baseline in the functioning/symptom/global quality of life (QoL) subscales of EORTC QLQ-C30. Scale scores range from 0-100. For functioning and global QoL scales, higher scores indicate better functioning or global health status. For symptom scales, higher scores indicate greater symptom burden.

    Time frame: Up to approximately 24 months.

  9. Patient reported outcomes (PROs): EORTC QLQ-BR45

    Change from baseline in the functioning/symptom subscales of EORTC QLQ-BR45. Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden.

    Time frame: Up to approximately 24 months.

  10. Patient reported outcomes (PROs): European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L)

    Change from baseline in EQ-5D-5L health state utility index score and Visual Analogue Scale (VAS) score. VAS score range from 0-100, higher scores indicate better health status.

    Time frame: Up to approximately 24 months.

  11. European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L)

    EQ-5D-5L health state utility index score and Visual Analogue Scale (VAS) score. The change from baseline value will be reported.

    Time frame: Up to approximately 24 months.

  12. Anti-drug antibodies (ADA)

    Number and percentage of patients who develop anti-drug antibody (ADA) for DB-1303/BNT323.

    Time frame: Up to approximately 24 months.

07

Study locations

48 sites
  • 015
    Bengbu, Anhui 233000, China
  • 016
    Hefei, Anhui 230001, China
  • 029
    Hefei, Anhui 230601, China
  • 001
    Beijing, Beijing Municipality 100039, China
  • 010
    Beijing, Beijing Municipality 100142, China
  • 038
    Jilin City, Changchun 130022, China
  • 036
    Fuzhou, Fujian 350014, China
  • 037
    Xiamen, Fujian 361003, China
  • 023
    Guangzhou, Guangdong 510060, China
  • 024
    Guangzhou, Guangdong 510080, China
  • 026
    Guangzhou, Guangdong 510120, China
  • 028
    Huizhou, Guangdong 516001, China
  • 017
    Nanning, Guangxi 530021, China
  • 022
    Nanning, Guangxi 530021, China
  • 043
    Haikou, Hainan 570102, China
  • 045
    Baoding, Hebei 071000, China
  • 048
    Shijiazhuang, Hebei 050011, China
  • 020
    Haerbin, Heilongjiang 150081, China
  • 018
    Luoyang, Henan 471003, China
  • 006
    Zhengzhou, Henan 450003, China
  • 005
    Zhengzhou, Henan 450052, China
  • 011
    Wuhan, Hubei 430030, China
  • 009
    Wuhan, Hubei 430079, China
  • 030
    Changsha, Hunan 410005, China
  • 027
    Nanjing, Jiangsu 210009, China
  • 004
    Nanjing, Jiangsu 210029, China
  • 044
    Xuzhou, Jiangsu 221006, China
  • 014
    Nanchang, Jiangxi 330006, China
  • 008
    Changchun, Jilin 130021, China
  • 032
    Dalian, Liaoning 116021, China
  • 040
    Binzhou, Shandong 256603, China
  • 031
    Jinan, Shandong 250013, China
  • 047
    Jinan, Shandong 250117, China
  • 012
    Linyi, Shandong 276003, China
  • 039
    Yantai, Shandong 264001, China
  • 002
    Shanghai, Shanghai Municipality 200032, China
  • 046
    Shanghai, Shanghai Municipality 200120, China
  • 035
    Taiyuan, Shanxi 030013, China
  • 003
    Xi’an, Shanxi 710061, China
  • 007
    Chengdu, Sichuan 610041, China
  • 041
    Neijiang, Sichuan 641100, China
  • 034
    Yibin, Sichuan 644000, China
  • 021
    Tianjin, Tianjin Municipality 300060, China
  • 013
    Ürümqi, Xinjiang 830011, China
  • 033
    Kunming, Yunnan 650118, China
  • 019
    Hangzhou, Zhejaing 310022, China
  • 025
    Hangzhou, Zhejiang 310003, China
  • 042
    Hangzhou, Zhejiang 310016, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 47 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Feb 2026 → Dec 2027 and completion Feb 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2024
First posted
Feb 20, 2024
StartActual
Jan 29, 2024
Primary completionEst.
Dec 2027was Feb 2026
CompletionEst.
Dec 2028was Feb 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 2026→Dec 2027
Oct 30, 2026
Study completion
Feb 2026→Dec 2028
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Primary completion Feb 2026→Dec 2027
    Study completion Feb 2026→Dec 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06265428
Lead sponsor
DualityBio Inc.
Collaborators
BioNTech SE
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Jan 29, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Lily Hu
study director · DualityBio Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab pamirtecan

Start the discussion